Morten is the CEO of Orbis Medicines, where he played a key role in building the company from the ground up while he was a Partner with Novo Holdings. With over 20 years of experience in venture investments, R&D, business development, corporate strategy, M&A, and company creation, Morten is a seasoned leader in the life sciences industry. Previously, Morten served as Partner at Novo Holdings a global life science focused investment fund. Prior to that he was Director of Corporate Development at H. Lundbeck A/S, where he led strategic acquisitions and partnerships, including the successful acquisition of Chelsea Therapeutics for USD 658 million. He also spearheaded the spin-out and financing of Syndesi Therapeutics, which was acquired by Abbvie for USD 1 billion. Morten holds an MSc in Human Biology from the University of Copenhagen.